Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019066519) PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF AGE-RELATED MACULAR DEGENERATION CONTAINING RNA COMPLEX TARGETING CONNECTIVE TISSUE GROWTH FACTOR
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2019/066519 International Application No.: PCT/KR2018/011482
Publication Date: 04.04.2019 International Filing Date: 28.09.2018
IPC:
A61K 48/00 (2006.01) ,A61K 31/713 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
70
Carbohydrates; Sugars; Derivatives thereof
7088
Compounds having three or more nucleosides or nucleotides
713
Double-stranded nucleic acids or oligonucleotides
Applicants:
올릭스 주식회사 OLIX PHARMACEUTICALS, INC. [KR/KR]; 경기도 수원시 영통구 대학4로 17 1014호 No.1014 17, Daehak 4-ro, Yeongtong-gu Suwon-si Gyeonggi-do 16226, KR
Inventors:
이동기 LEE, Dong Ki; KR
김영희 KIM, Young Hee; KR
홍선우 HONG, Sun Woo; KR
Agent:
이처영 LEE, Cheo Young; KR
장제환 CHANG, Je Hwan; KR
Priority Data:
10-2017-012638728.09.2017KR
Title (EN) PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF AGE-RELATED MACULAR DEGENERATION CONTAINING RNA COMPLEX TARGETING CONNECTIVE TISSUE GROWTH FACTOR
(FR) COMPOSITION PHARMACEUTIQUE POUR LA PRÉVENTION OU LE TRAITEMENT DE LA DÉGÉNÉRESCENCE MACULAIRE LIÉE À L'ÂGE CONTENANT UN COMPLEXE D'ARN CIBLANT LE FACTEUR DE CROISSANCE DU TISSU CONJONCTIF
(KO) 결합 조직 성장 인자를 표적으로 하는 RNA 복합체를 함유하는 노인성 황반변성의 예방 또는 치료용 약학 조성물
Abstract:
(EN) The present invention relates to a pharmaceutical composition for prevention or treatment of age-related macular degeneration (AMD) comprising an RNA complex targeting connective tissue growth factor (CTGF) as an active ingredient and, more specifically, to a pharmaceutical composition for prevention or treatment of age-related macular degeneration comprising an RNA complex as an active ingredient, the composition comprising: an antisense strand including a region complementary to an mRNA encoding connective tissue growth factor; and a sense strand forming a complementary bond with the antisense strand, wherein the antisense strand and the sense strand form blunt ends at the 5' end of the antisense strand and the 3' end of the sense strand. The pharmaceutical composition according to the present invention may be used as an effective and safe AMD therapeutic agent, prevent many AMD patients from losing their sight, thereby improving the quality of life, and save enormous social costs, and thus is useful.
(FR) La présente invention concerne une composition pharmaceutique pour la prévention ou le traitement de la dégénérescence maculaire liée à l'âge (DMLA) comprenant en tant que principe actif un complexe d'ARN ciblant le facteur de croissance du tissu conjonctif (CTGF), et, plus spécifiquement, une composition pharmaceutique pour la prévention ou le traitement de la dégénérescence maculaire liée à l'âge comprenant en tant que principe actif un complexe d'ARN, la composition comprenant : un brin antisens comprenant une région complémentaire d'un ARNm codant pour le facteur de croissance du tissu conjonctif ; et un brin sens formant une liaison complémentaire avec le brin antisens, le brin antisens et le brin sens formant des extrémités franches à l'extrémité 5' du brin antisens et l'extrémité 3' du brin sens. La composition pharmaceutique de la présente invention peut être utilisée en tant qu'agent thérapeutique efficace et sûr contre la DMLA, prévient la perte de la vue chez de nombreux patients atteints de DMLA, ce qui permet d'améliorer la qualité de vie, et économise des coûts sociaux énormes, et est donc utile.
(KO) 본 발명은 결합 조직 성장 인자(CTGF)를 표적으로 하는 RNA 복합체를 유효성분으로 포함하는 노인성 황반변성(AMD)의 예방 또는 치료용 약학 조성물에 관한 것으로, 보다 상세하게는 결합 조직 성장 인자를 코딩하는 mRNA와 상보적인 영역을 포함하는 안티센스 가닥과, 상기 안티센스 가닥과 상보적 결합을 형성하는 센스 가닥을 포함하고, 상기 안티센스 가닥과 센스 가닥은 안티센스 가닥의 5' 말단 및 센스 가닥의 3' 말단에서 블런트 말단을 형성하는 것을 특징으로 하는 RNA 복합체를 유효성분으로 포함하는 노인성 황반변성의 예방 또는 치료용 약학 조성물에 관한 것이다. 본 발명에 따른 약학 조성물은 효과적이고 안전한 AMD 치료제로 활용될 수 있으며, 많은 AMD 환자들이 시력을 잃지 않게 하여 삶의 질을 높이고, 막대한 사회적 비용을 절감할 수 있어 유용하다.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Korean (KO)
Filing Language: Korean (KO)